Lansoprazole is a ATP4A (H+,K+-ATPase) inhibitor (IC50 = 6.3 μM) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC50 = 0.09 µM for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacterial against Helicobacter pylori in vitro. Also blocks swelling-dependent chloride channel (ICI swell) in NIH3T3 fibroblasts. Lansoprazole is more potent than omeprazole (sc-202265).
Satoh et al (1989) Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J.Pharmacol.Exp.Ther. 248 806. Schmarda et al (2000 The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels. Br.J.Pharmacol. 129 598. Matheson and Jarvis (2001) Lansoprazole. Drugs 61 1801.
See how others have used Lansoprazole (CAS 103577-45-3). Click on the entry to view the PubMed entry .
PMID: # 25141173 Novotna, A. et al. 2014. PLoS ONE. 9: e105580.
PMID: # 24887303 Novotna, A. et al. 2014. PLoS ONE. 9: e98711.
PMID: # 23652407 Tamraz, B. et al. 2013. Pharmacogenet. Genomics. 23: 355-64.
PMID: # 32153057 Andrologia. e13564.